Constantiam Biosciences
PrivateLast Round
Seed
Jun 18, 2026
Est. Valuation
$0
Total Funding Raised
$23.95M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Constantiam Biosciences is a biotechnology company that develops precision medicine therapies and functional genomics platforms to decode human genetic variation for the treatment of severe genetic disorders.
Sector
Healthcare & Life Sciences
Verticals
Precision Medicine, Drug Discovery, Biotechnology, Healthcare Analytics, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Constantiam Biosciences Comparables
Compare Constantiam Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Heligenics, Inc. | 86% | |
| Ranomics | 82% | |
| Atlas Biotech | 80% |
Constantiam Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Jun 18, 2026 | ||||
| Grant | Sep 4, 2024 | ||||
| Series A | Oct 19, 2023 | ||||
| Grant | Feb 1, 2023 | ||||
| Grant | Aug 15, 2022 | ||||
Grant | Mar 1, 2021 |
Constantiam Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| NIH RADx | Grant |
| OrbiMed | Series A |
| National Institute on Aging | Grant |
| Atlas Venture | Series A |
| National Science Foundation | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 18, 2026
Completed a Seed funding round.
- Sep 4, 2024
Secured $2M from National Human Genome Research Institute and others.
Recent news
Latest coverage and updates
- receives_financingSep 22, 2026
Constantiam received financing of $2.5M in Phase II Small Business Innovation Research (SBIR) on Sep 22nd '26.
Constantiam Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Constantiam Biosciences's valuation, stock price, and market status.
Is Constantiam Biosciences a public or private company?
Constantiam Biosciences is a private company.
What is the current stock price of Constantiam Biosciences?
Constantiam Biosciences is a private company with no public stock price. No recent secondary market data is available.
How much is Constantiam Biosciences worth (valuation)?
Constantiam Biosciences's valuation is estimated at $0 based on funding round data.
Can I buy Constantiam Biosciences stock?
Constantiam Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Constantiam Biosciences's last funding round?
Constantiam Biosciences's most recent funding round was Grant on March 2, 2020.
Who are the main investors in Constantiam Biosciences?
Key investors in Constantiam Biosciences include NIH RADx, OrbiMed, Atlas Venture.
Will Constantiam Biosciences IPO soon?
No public IPO plans have been announced for Constantiam Biosciences.
How can I track Constantiam Biosciences secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Constantiam Biosciences's secondary market activity and sign up for updates.